XML 21 R12.htm IDEA: XBRL DOCUMENT
v3.26.1

Earnings per share | 3 Months Ended
--- | ---
Mar. 31, 2026
Earnings Per Share [Abstract] |
Earnings per share | ## (4) Earnings per share Since the Company reported a net loss for the three months ended March 31, 2026 and 2025, it was required by ASC 260 to use basic weighted-average shares outstanding when calculating diluted net loss per share for the three months ended March 31, 2026 and 2025, as the potential dilutive securities are anti-dilutive. The following is a reconciliation of the numerator and denominator used to calculate basic earnings per share and diluted earnings per share for the three months ended March 31, 2026 and 2025:
|  | For The Three Months Ended March 31, |
|  | 2026 |  |  | 2025 |
Calculation of basic loss per share attributable to the Company’s shareholders |  |  |  |  |  |
Net loss attributable to common stockholders |  |  | (18,868,885 | ) |  |  | (5,196,773 | )
Weighted-average common shares outstanding - basic and diluted |  |  | 53,558,639 |  |  |  | 9,291,641 |
Earnings per share - basic and diluted |  | $ | (0.35 | ) |  | $ | (0.56 | )
Included within weighted average common shares outstanding for the three months ended March 31, 2026, are 2,753,246 common shares issuable upon the exercise of pre-funded warrants, as the warrants are exercisable at any time for nominal consideration, and, as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders. The Company’s other potentially dilutive securities, which include stock options, restricted stock awards, common stock warrants, earnout shares, and contingently issuable earnout shares have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
|  | For The Three Months Ended March 31, |
|  | 2026 |  |  | 2025 |
Stock options and awards |  |  | 38,970,396 |  |  |  | 2,983,234 |
Common Stock Warrants (1) |  |  | 2,233,407 |  |  |  | 2,233,407 |
Series A Preferred Stock (2) |  |  | 4,504,824 |  |  |  | 6,669,742 |
Preferred Stock Warrants (3) |  |  | 17,002,381 |  |  |  | 17,002,381 |
Enrollment Warrants (4) |  |  | 98,300,000 |  |  |  | — |
Release Date Warrants (4) |  |  | 50,000,000 |  |  |  | — |
Contingently issuable Earnout Shares from unexercised Rollover Options |  |  | 150,806 |  |  |  | 150,806 |
Total |  |  | 211,161,814 |  |  |  | 29,039,570 |
(1) Contained within common stock warrants are the 575,000 shares of common stock underlying public warrants (the “Public Warrants”), 20,860 shares of common stock underlying warrants held by assignees of Big Cypress Holdings, LLC (the “Private Placement Warrants”), 30,000 shares underlying warrants held by Ladenburg Thalmann & Co. Inc. (the “Ladenburg Warrants”), 736,337 shares underlying warrants issued to the investors in the December 2022 Private Placement (the “the PIPE Warrants”), 21,091 shares underlying warrants issued to the placement agent in the December 2022 Private Placement (the “PIPE Placement Agent Warrants”), and 850,119 shares underlying the Preferred PIPE Placement Agent Warrants issued to the placement agent in the September 2023 Offering. See Note 10, Warrants for further details on the Company’s outstanding warrants. (2) Represents 4,504,824 and 6,669,742 shares of common stock underlying 28,380 and 42,019 issued and outstanding shares of Series A-2 Preferred Stock, for the three months ended March 31, 2026 and 2025, respectively. See Note 8, Stockholders’ Equity for further details on the Company’s preferred stock. (3) Represents 17,002,381 shares of common stock underlying 107,115 outstanding Preferred Tranche C Warrants (as defined below) for the three months ended March 31, 2026. See Note 10, Warrants for further details on the Company’s outstanding warrants. (4) Represents 50,000,000 and 98,300,000 shares of common stock underlying the Release Date Warrants and Enrollment Warrants, respectively, for the three months ended March 31, 2026.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration